menu
    • menu
    [{"orgOrder":0,"company":"Auditus","sponsor":"Oblato","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Acetylcysteine","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"Auditus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Auditus \/ Oblato","highestDevelopmentStatusID":"8","companyTruncated":"Auditus \/ Oblato"}]

    Find Clinical Drug Pipeline Developments & Deals for 2,4-disulfonyl alpha-phenyl tertiary butyl nitrone

    Menu

    2,4-disulfonyl alpha-phenyl tertiary butyl nitrone

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Auditus

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Auditus

                            Country arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acetylcysteine,2,4-disulfonyl alpha-phenyl tertiary butyl nitrone

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : Oblato

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Oblato Biotech Company Acquires Hearing Loss Drug

                            Details : Oblato assumes exclusive rights to a drug known as NHPN-1010. Oblato is expected to initiate a phase 2 clinical trial to evaluate the potential of the drug to prevent and treat hearing loss.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 12, 2020

                            Lead Product(s) : Acetylcysteine,2,4-disulfonyl alpha-phenyl tertiary butyl nitrone

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : Oblato

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth